Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01XDL
|
|||
| Former ID |
DAP000050
|
|||
| Drug Name |
Idarubicin
|
|||
| Synonyms |
DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Approved | [1], [2] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Ben Venue Laboratories
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H27NO9
|
|||
| Canonical SMILES |
CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O
|
|||
| InChI |
1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1
|
|||
| InChIKey |
XDXDZDZNSLXDNA-TZNDIEGXSA-N
|
|||
| CAS Number |
CAS 58957-92-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
794734, 7887077, 7979585, 8177897, 11378086, 14810780, 14908709, 17405162, 24278488, 26697284, 26704230, 26704281, 34708383, 46506973, 47959947, 48416101, 49995025, 50106402, 50106403, 50106404, 53777706, 53788391, 57312753, 79820214, 85789484, 87325144, 90340569, 92303774, 92308741, 96024754, 103311042, 104340903, 117597729, 117695696, 121361286, 124749845, 124891657, 126626724, 126661729, 127301008, 127301009, 127301010, 127301011, 127301012, 127301013, 127301014, 127301015, 127301016, 127301017, 127301018
|
|||
| ChEBI ID |
CHEBI:42068
|
|||
| ADReCS Drug ID | BADD_D01127 ; BADD_D01128 | |||
| SuperDrug ATC ID |
L01DB06
|
|||
| SuperDrug CAS ID |
cas=058957929
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Escherichia coli Nissle 1917
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Metabolic Effect | Decrease activity | |||
| Description | Idarubicin can be metabolized by Escherichia coli Nissle 1917, which results in the decrease of the drug's activity. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA topoisomerase II (TOP2) | Target Info | Modulator | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7083). | |||
| REF 2 | New drugs for the treatment of cancer, 1990-2001. Isr Med Assoc J. 2002 Dec;4(12):1124-31. | |||
| REF 3 | Local bacteria affect the efficacy of chemotherapeutic drugs. Sci Rep. 2015 Sep 29;5:14554. | |||
| REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.